During the Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the Lymphoma, Leukemia & Myeloma Congress, Javier Pinilla-Ibarz, MD, PhD, debated that BTK inhibitors are the preferred treatment regimen for patients with CLL.
During the Lymphoma, Leukemia &...